We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AOH1996
Previous Study | Return to List | Next Study

AOH1996 for the Treatment of Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05227326
Recruitment Status : Recruiting
First Posted : February 7, 2022
Last Update Posted : October 3, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease Intervention/treatment Phase
Refractory Malignant Solid Neoplasm Drug: PCNA Inhibitor AOH1996 Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of PCNA inhibitor AOH1996 (AOH1996).

II. To establish the recommended phase 2 dose (RP2D) of AOH1996.

SECONDARY OBJECTIVES:

I. To determine the pharmacokinetics of AOH1996. II. To evaluate for preliminary efficacy of AOH1996. III. To evaluate response rate and disease control rate in solid tumors.

EXPLORATORY OBJECTIVE:

I. To determine pharmacodynamics parameters (alteration of gammaH2AX, downregulation of Myc) of AOH1996.

OUTLINE: This is a dose-escalation study.

Patients receive AOH1996 orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors
Actual Study Start Date : August 12, 2022
Estimated Primary Completion Date : March 30, 2024
Estimated Study Completion Date : March 30, 2024

Arm Intervention/treatment
Experimental: Treatment (PCNA inhibitor AOH1996)
Patients receive PCNA inhibitor AOH1996 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: PCNA Inhibitor AOH1996
Given PO
Other Names:
  • AOH 1996
  • AOH-1996
  • AOH1996
  • Proliferating Cell Nuclear Antigen Inhibitor AOH1996




Primary Outcome Measures :
  1. Incidence of adverse events (AEs) [ Time Frame: Up to 30 days after last study drug is given ]
    Toxicity and adverse events will be recorded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. All toxicities/AEs will be recorded from the initiation of protocol therapy through the follow-up period.

  2. Dose limiting toxicities [ Time Frame: Up to 28 days (cycle 1) ]
    Toxicities will be graded according to NCI CTCAE version 4.0.


Secondary Outcome Measures :
  1. Response rate [ Time Frame: Up to 2 years ]
    Will be assessed using Response Evaluation Criteria in Solid Tumors version 1. Response rate will be estimated in the overall population and 95% exact confidence intervals will be estimated.

  2. Progression-free survival [ Time Frame: Assessed up to 2 years ]
    Time to disease progression/ relapse or death as a result of any cause.

  3. Overall survival [ Time Frame: Assessed up to 2 years ]
    Time to death as a result of any cause.

  4. Time to treatment failure [ Time Frame: Assessed up to 2 years ]
    Time to treatment termination for any reason (progression, toxicity, death, patient preference).


Other Outcome Measures:
  1. Levels of plasma gammaH2AX [ Time Frame: Up to 2 years ]
    Will use descriptive statistics and graphical displays to summarize levels of plasma gammaH2AX, evaluate changes between pre- and post-treatment measurements. A paired t-test will be used to determine if there is a statistically significant change.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented informed consent by the participant
  • Willingness to permit study team to obtain and use archival tissue, if already existing
  • Age: >= 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Life expectancy of > 3 months
  • Patients with solid tumors failing standard therapies or patients refusing standard treatments
  • Agreement by females and males of childbearing potential to use an adequate method of birth control (hormonal contraception is inadequate) or abstain from heterosexual activity for the course of the study through 30 days after the last dose of study medication

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
  • Absolute neutrophil count (ANC) >= 1,500/mm^3 (performed within 14 days prior to day 1)
  • Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (performed within 14 days prior to day 1)
  • Aspartate aminotransferase (AST) =< 1.5 x ULN or =< 3 x ULN with liver metastases (performed within 14 days prior to day 1)
  • Alanine aminotransferase (ALT) =< 1.5 x ULN or =< 3 x ULN with liver metastases (performed within 14 days prior to day 1)
  • Creatinine clearance of >= 60 mL/min per 24 hour urine or the Cockcroft-Gault (performed within 14 days prior to day 1)
  • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Exclusion Criteria:

  • Concomitant medications/therapies

    • Dietary/herbal supplements
    • Other investigational products
    • Warfarin
    • Current or planned use of agents contraindicated for use with strong CYP3A4 inducers
    • Strong inhibitors or inducers of CYP2C9
    • Strong inhibitors or inducers of CYP3A
  • Issues with tolerating oral medication (e.g. inability to swallow pills, malabsorption issues, ongoing nausea or vomiting)
  • Women who are or are planning to become pregnant or breastfeed
  • Known allergy to any of the components within the study agents and/or their excipients
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years
  • Intercurrent or historic medical condition that increases subject risk in the opinion of the Investigator. Eligibility may be revisited for intercurrent medical conditions once resolution/recovery is deemed adequate by the investigator (e.g. recovery from major surgery, completion of treatment for severe infection)
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05227326


Locations
Layout table for location information
United States, Arizona
HonorHealth Research Institute Not yet recruiting
Scottsdale, Arizona, United States, 85258
Contact: Vincent Chung    626-218-9200    vchung@coh.org   
Principal Investigator: Vincent Chung         
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Vincent Chung    626-218-9200    vchung@coh.org   
Principal Investigator: Vincent Chung         
Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Vincent Chung City of Hope Medical Center
Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT05227326    
Other Study ID Numbers: 21310
NCI-2021-14102 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
21310 ( Other Identifier: City of Hope Medical Center )
P30CA033572 ( U.S. NIH Grant/Contract )
First Posted: February 7, 2022    Key Record Dates
Last Update Posted: October 3, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No